Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVTXNASDAQ:CDTOTCMKTS:INTINASDAQ:KPTI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVTXAvalo Therapeutics$3.59-0.8%$5.15$3.39▼$16.00$38.87M0.8754,092 shs33,432 shsCDTConduit Pharmaceuticals$3.69-0.5%$8.60$3.25▼$4,710.00$2.95M2.39112,477 shs84,890 shsINTIInhibitor Therapeutics$0.05-15.1%$0.05$0.03▼$0.10$8.63M-0.4337,239 shs80,000 shsKPTIKaryopharm Therapeutics$4.48-1.5%$5.10$3.51▼$17.40$38.71M0.3382,066 shs86,849 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVTXAvalo Therapeutics-3.47%-11.71%-24.27%-45.97%-72.37%CDTConduit Pharmaceuticals+6.61%-35.48%-56.03%-78.68%-99.91%INTIInhibitor Therapeutics-15.11%-10.71%-16.11%-24.16%-53.62%KPTIKaryopharm Therapeutics-0.87%-11.82%-19.04%-53.71%-71.11%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVTXAvalo Therapeutics3.532 of 5 stars4.43.00.00.02.51.71.3CDTConduit Pharmaceuticals0.3954 of 5 stars0.04.00.00.02.20.00.0INTIInhibitor Therapeutics0.4819 of 5 stars0.05.00.00.01.70.00.0KPTIKaryopharm Therapeutics3.9731 of 5 stars3.50.00.04.63.62.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVTXAvalo Therapeutics 2.83Moderate Buy$33.00819.22% UpsideCDTConduit Pharmaceuticals 4.00Strong BuyN/AN/AINTIInhibitor Therapeutics 0.00N/AN/AN/AKPTIKaryopharm Therapeutics 3.00Buy$43.20864.29% UpsideCurrent Analyst Ratings BreakdownLatest INTI, AVTX, KPTI, and CDT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025KPTIKaryopharm TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$34.00 ➝ $33.005/13/2025KPTIKaryopharm TherapeuticsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$5.00 ➝ $10.005/13/2025KPTIKaryopharm TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$54.00 ➝ $42.003/25/2025AVTXAvalo TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageUnderperform ➝ Buy$23.003/25/2025AVTXAvalo TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$36.003/20/2025AVTXAvalo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral3/20/2025AVTXAvalo TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$18.003/3/2025KPTIKaryopharm TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$75.00 ➝ $54.002/28/2025AVTXAvalo TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$48.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVTXAvalo Therapeutics$441K88.15N/AN/A$9.11 per share0.39CDTConduit PharmaceuticalsN/AN/AN/AN/A($0.62) per shareN/AINTIInhibitor TherapeuticsN/AN/AN/AN/A$0.03 per shareN/AKPTIKaryopharm Therapeutics$142.13M0.27N/AN/A($1.47) per share-3.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVTXAvalo Therapeutics-$31.54MN/A0.00N/AN/AN/A-442.16%122.99%8/11/2025 (Estimated)CDTConduit Pharmaceuticals-$540K-$534.48N/A∞N/AN/AN/A-328.67%N/AINTIInhibitor Therapeutics-$3.03M-$0.01N/A∞N/AN/A-70.65%-40.64%8/4/2025 (Estimated)KPTIKaryopharm Therapeutics-$143.10M-$13.26N/AN/AN/A-52.62%N/A-39.58%8/5/2025 (Estimated)Latest INTI, AVTX, KPTI, and CDT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025CDTConduit PharmaceuticalsN/A-$19.80N/A-$1.32N/AN/A5/12/2025Q1 2025AVTXAvalo Therapeutics-$1.07-$1.25-$0.18-$1.25N/AN/A5/12/2025Q1 2025KPTIKaryopharm Therapeutics-$4.21-$2.77+$1.44-$2.77$35.12 million$30.02 million3/28/2025Q4 2024CDTConduit PharmaceuticalsN/A-$304.95N/A-$20.33N/AN/A3/28/2025Q4 2024INTIInhibitor TherapeuticsN/A-$0.01N/A-$0.01N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVTXAvalo TherapeuticsN/AN/AN/AN/AN/ACDTConduit PharmaceuticalsN/AN/AN/AN/AN/AINTIInhibitor TherapeuticsN/AN/AN/AN/AN/AKPTIKaryopharm TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVTXAvalo TherapeuticsN/A1.421.42CDTConduit PharmaceuticalsN/A0.120.12INTIInhibitor TherapeuticsN/A144.77144.77KPTIKaryopharm TherapeuticsN/A1.702.93Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVTXAvalo Therapeutics87.06%CDTConduit Pharmaceuticals3.29%INTIInhibitor TherapeuticsN/AKPTIKaryopharm Therapeutics66.44%Insider OwnershipCompanyInsider OwnershipAVTXAvalo Therapeutics3.03%CDTConduit Pharmaceuticals4.05%INTIInhibitor Therapeutics4.60%KPTIKaryopharm Therapeutics2.75%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVTXAvalo Therapeutics4010.83 million10.37 millionNot OptionableCDTConduit Pharmaceuticals3798,000710,000Not OptionableINTIInhibitor Therapeutics1172.57 million164.34 millionNot OptionableKPTIKaryopharm Therapeutics3808.64 million122.72 millionOptionableINTI, AVTX, KPTI, and CDT HeadlinesRecent News About These CompaniesHere's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock NowMay 26 at 10:55 AM | zacks.comDoes Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect?May 19, 2025 | zacks.comKaryopharm to Participate at the 2025 RBC Capital Markets Global Healthcare ConferenceMay 19, 2025 | prnewswire.comBrokerages Set Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target at $45.60May 18, 2025 | americanbankingnews.comRobert W. Baird Issues Pessimistic Forecast for Karyopharm Therapeutics (NASDAQ:KPTI) Stock PriceMay 15, 2025 | marketbeat.comKaryopharm Therapeutics (NASDAQ:KPTI) Posts Earnings Results, Beats Estimates By $1.44 EPSMay 14, 2025 | marketbeat.comKaryopharm Announces Poster Presentation on Selinexor in Myelofibrosis at the 2025 European Hematology Association Annual MeetingMay 14, 2025 | prnewswire.comKaryopharm Therapeutics (KPTI) Reports Q1 Loss, Lags Revenue EstimatesMay 12, 2025 | zacks.comKaryopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hemoglobin Stabilization and Disease ModificationMay 12, 2025 | prnewswire.comKaryopharm Therapeutics (KPTI) to Release Earnings on WednesdayMay 9, 2025 | marketbeat.comKaryopharm Therapeutics (NASDAQ:KPTI) Stock Price Passes Below 200 Day Moving Average - Here's WhyMay 9, 2025 | marketbeat.comKaryopharm to Report First Quarter 2025 Financial Results on May 12, 2025May 8, 2025 | prnewswire.comWhy Karyopharm Therapeutics Inc.’s (KPTI) Stock Is Down 5.15%May 6, 2025 | aaii.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2025 | prnewswire.comKaryopharm Therapeutics Inc.DL-Exch. Notes 2018(25) BondMay 1, 2025 | markets.businessinsider.comWhy Karyopharm Therapeutics Inc.’s (KPTI) Stock Is Up 5.06%April 30, 2025 | aaii.comKaryopharm Therapeutics (NASDAQ:KPTI) Shares Cross Below 200-Day Moving Average - Here's WhyApril 30, 2025 | marketbeat.comKaryopharm Therapeutics Inc. Common Stock (KPTI)April 23, 2025 | nasdaq.comKaryopharm Therapeutics Inc. Common Stock (KPTI)April 23, 2025 | nasdaq.comKaryopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)April 1, 2025 | prnewswire.comKaryopharm price target lowered to split-adjusted $15 from $75 at Piper SandlerMarch 20, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongNavitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookBy Leo Miller | May 27, 2025View Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and OutlookWhat Ray Dalio's Latest Moves Tell Investors By Gabriel Osorio-Mazilli | May 19, 2025View What Ray Dalio's Latest Moves Tell Investors What the New Quarter Says About Super Micro Computer's FutureBy Gabriel Osorio-Mazilli | May 7, 2025View What the New Quarter Says About Super Micro Computer's FutureINTI, AVTX, KPTI, and CDT Company DescriptionsAvalo Therapeutics NASDAQ:AVTX$3.59 -0.03 (-0.83%) Closing price 04:00 PM EasternExtended Trading$3.76 +0.17 (+4.76%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. The company's drug candidates include AVTX-009, an Anti-IL-1ß monoclonal antibody which is under Phase I targeting inflammatory diseases; and AVTX-008, a fully human B and T lymphocyte attenuator agonist fusion protein for the treatment of immune dysregulation disorders. It also develops Quisovalimab (AVTX-002), an Anti-LIGHT mAb which is in phase II for immune-inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.Conduit Pharmaceuticals NASDAQ:CDT$3.69 -0.02 (-0.54%) Closing price 04:00 PM EasternExtended Trading$3.72 +0.02 (+0.68%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Conduit Pharmaceuticals Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. The company was founded in 2019 and is based in San Diego, California. Conduit Pharmaceuticals Limited is a subsidiary of Corvus Capital Limited.Inhibitor Therapeutics OTCMKTS:INTI$0.05 -0.01 (-15.11%) As of 05/27/2025 11:08 AM EasternInhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. The company engages in the development of therapies for prostate and lung cancer utilizing itraconazole; and conducted a positive Phase 2b clinical trial of SUBA-Itraconazole for the treatment of basal cell carcinoma nevus syndrome. It has license agreement with Johns Hopkins University. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics, Inc. in August 2019. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics, Inc operates as a subsidiary of Mayne Pharma Ventures Pty Ltd.Karyopharm Therapeutics NASDAQ:KPTI$4.48 -0.07 (-1.54%) Closing price 04:00 PM EasternExtended Trading$4.58 +0.10 (+2.23%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock GameStop Buys Bitcoin: Smart Strategy or Big Mistake? Qualcomm Stock Turns South: 3 Entry Signals to Watch For D-Wave Quantum Stock: Are Advantage2 Gains Here to Stay? Meta's Institutional & Insider Data Fuels Bulls Despite Disparity Is Michael Burry Right Betting Against the Market Again? Amer Sports: The New ONON and DECK of Consumer Discretionary? BigBear.ai: Risky AI Stock or Defense Tech Opportunity? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
